Clinical Trial

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

Withdrawn Phase 2/3
View on ClinicalTrials.gov →
Why the trial stopped
Recruitment for end-points deemed not feasible.
Summary
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics. Participants in this study will be placed randomly into two groups. The oral vancomycin treatment group will receive oral vancomycin two times per day simultaneously with an antibiotic plus two additional days. The no oral vancomycin control group will receive the current standard of care, which is an antibiotic and no oral vancomycin. Participation in this study will last approximately 3 months.
Protocol Amendment History 3 changes
critical Withdrawn before enrolling 2026-07-30
critical Trial withdrawn: Recruitment for end-points deemed not feasible. 2026-07-30
notable Enrollment reduced: 200 -> 0 participants 2026-07-30
Trial Details
NCT Number NCT07221708
Lead Sponsor University of Maryland, Baltimore
Collaborators: University of Maryland, Baltimore Washington Medical Center
Conditions Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Start Date 2027-01-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-29